Nano-X Imaging Ltd. (NNOX)
NASDAQ: NNOX · Real-Time Price · USD
4.130
-0.230 (-5.28%)
At close: Nov 24, 2025, 4:00 PM EST
4.179
+0.049 (1.19%)
After-hours: Nov 24, 2025, 7:59 PM EST
Nano-X Imaging Employees
Nano-X Imaging had 165 employees as of December 31, 2024. The number of employees increased by 1 or 0.61% compared to the previous year.
Employees
165
Change (1Y)
1
Growth (1Y)
0.61%
Revenue / Employee
$74,558
Profits / Employee
-$337,612
Market Cap
270.03M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 165 | 1 | 0.61% |
| Dec 31, 2023 | 164 | -16 | -8.89% |
| Dec 31, 2022 | 180 | -6 | -3.23% |
| Dec 31, 2021 | 186 | 136 | 272.00% |
| Dec 31, 2020 | 50 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NNOX News
- 13 hours ago - Nanox.AI Bone Solutions, Advanced AI-Powered Software for Spine Assessment, Recommended by NICE for Early Value Assessment in UK National Health Service hospitals - GlobeNewsWire
- 22 hours ago - Nanox Announces $15 Million Registered Direct Offering of Common Stock - GlobeNewsWire
- 4 days ago - Nano-X Imaging Ltd. (NNOX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Vaso Corporation Announces Divestiture of Subsidiary - GlobeNewsWire
- 5 days ago - Nanox Reaches Agreement with Vaso Corporation to Acquire VasoHealthcare IT, Accelerating U.S. Rollout of AI Solutions - GlobeNewsWire
- 11 days ago - Nanox to Launch FDA-Cleared Nanox.ARC X and Present development of new AI innovations at RSNA 2025 Annual Meeting - GlobeNewsWire
- 2 months ago - Nanox Announces Multi-Segment Healthcare Collaboration with Monarch Medical Management to Expand Access to Advanced Medical Imaging - GlobeNewsWire
- 3 months ago - Top 3 Health Care Stocks You'll Regret Missing This Quarter - Benzinga